Skip to content

Advertisement

  • Case report
  • Open Access
  • Open Peer Review

A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus – clinical significance and possible mechanisms: a case report

Journal of Medical Case Reports201812:40

https://doi.org/10.1186/s13256-017-1550-6

  • Received: 30 October 2017
  • Accepted: 21 December 2017
  • Published:
Open Peer Review reports

Abstract

Background

In general, dexamethasone is a required component drug in various combination chemotherapies for treating multiple myeloma, and its efficacy has been widely recognized. However, administration of dexamethasone is known to cause various adverse effects including hyperglycemia which requires insulin therapy. During the course of treatment, we developed a novel effective dexamethasone-free combination regimen and evaluated it for its effect in multiple myeloma.

Case presentation

We report a case of 68-year-old Japanese woman with refractory advanced Bence-Jones-λ type multiple myeloma associated with diabetes mellitus. Various combination regimens were carried out, but the response to some regimens was insufficient or others containing dexamethasone, although effective, were inappropriate to continue due to aggravation of diabetes mellitus. Thus, we developed a dexamethasone-free, short dosing-period regimen consisting of bortezomib, lenalidomide, and clarithromycin. This regimen was found to be highly effective and succeeded in achieving stringent complete response.

Conclusions

The successful dexamethasone-free regimen clearly shows that dexamethasone is not a requisite component in treating multiple myeloma, and it can be substituted with clarithromycin. This regimen is particularly useful for treating patients with multiple myeloma associated with diabetes mellitus.

Keywords

  • Combination chemotherapy
  • Clarithromycin
  • Diabetes mellitus
  • Refractory multiple myeloma
  • Stringent complete response

Background

Lenalidomide (Len; Revlimid®) has been used in combination with dexamethasone (Dex) for treating relapsed/refractory multiple myeloma (MM) [1], newly diagnosed MM [2, 3], and transplant-ineligible MM [4]. Subsequently, bortezomib (Bor; Velcade®), the first-in-class proteasome inhibitor of the 26S proteasome, was approved in combination with Dex for treating newly diagnosed MM prior to autologous stem cell transplantation [5]. Recently, both drugs have been widely used for treating MM. In general, high-dose/low-dose Dex is a requisite component in various combination chemotherapies for treating MM, and its efficacy has been recognized. However, administration of Dex is known to cause various adverse effects including hyperglycemia leading to secondary diabetes mellitus (DM), DM-aggravation, DM-nephropathy, DM-retinopathy, reactivation of hepatitis virus B leading to fulminant hepatitis, increased susceptibility to infections, Cushing syndrome, psychic disturbance like delirium, systemic osteoporosis, cataract, and so on. Sometimes, clinicians have to treat patients with MM who also have DM. In such cases, regimens that include Dex induce severe hyperglycemia which requires insulin therapy. We treated a patient with refractory Bence-Jones (BJ)-λ type MM associated with DM, and succeeded in achieving stringent complete response (sCR) with a Dex-free, short dosing-period (sdp) regimen in which clarithromycin (CAM) was combined with Bor and Len.

Case presentation

Our patient was a 68-year-old Japanese woman (48 kg/151 cm) with a 7-year history of DM. She had a past history of receiving a radical mastectomy for right mammary cancer in the department of surgery of our hospital at the age of 65. Her postoperative course was uneventful. After the operation, she received chemotherapies (trastuzumab, paclitaxel, and tegafur-uracil) until the end of December 2014, and later she was followed without treatment on an out-patient basis. In March 2015, she showed progressive unexplained anemia. On 4 June 2015, she was admitted to the surgical department of our hospital at the age of 68 because of anemia, abdominal pain, paralytic ileus, generalized neuralgia-like pains, and bilateral shoulder joint swellings and pains. On 13 June 2015, she was referred and admitted to the hematologic division for further evaluation.

Physical examinations on admission were as follows. Her temperature was 36.5 °C, her pulse was 88, and her blood pressure was 130 systolic and 85 diastolic. Her right mamma was completely removed with a remaining operation scar. She appeared chronically ill and could not turn over due to generalized neuralgia-like pains and severe right shoulder pains. Her skin showed pallor and palpebral conjunctivae were anemic. Her abdomen was distended, tympanitic, and diffusely tender without peristalsis, indicating paralytic ileus. Superficial lymph nodes were impalpable.

Laboratory data on admission were as follows. A complete blood cell count showed moderate anemia (red blood cell count, 2.31 × 1012/L; hemoglobin 7.4 g/dL), slightly increased leukocytes (white blood cell count, 9.5 × 109/L with 67.5% neutrophils, 17.5% lymphocytes, and 13% monocytes, 2% eosinophils) and normal platelet count (301 × 109/L). Elevated levels of serum free light chain-λ (FLC-λ; more than 3200 mg/L; normal range (nr.), 4.44~26.18 mg/L), β2-microglobulin (BMG; 6.5 mg/L; nr. 0.9~1.9 mg/L), soluble-interleukin (IL)-2 receptors (1300 U/mL; nr. 124~466 U/mL), ferritin (955.6 ng/mL; nr. 3.6~114 pg/mL), CRP (1.74 mg/dL; nr. 0~0.26 mg/dL), D-dimer (8.69 μg/mL; nr. < 0.72 μg/mL), and fibrin degradation product (FDP; 20.1 μg/mL; nr. < 5 μg/mL), N-terminal pro-brain natriuretic peptide (NT-proBNP; 191 pg/mL; nr. ≤ 125 pg/mL), CA19-9 (42 U/mL; nr. ≤ 37 U/mL), sialyl-Lex-i (SLX; 42.8 U/mL; nr. ≤ 38 U/mL), glycated hemoglobin (HbA1c; 6.7%; nr. 4.54~6.25%) and uric acid (7.2 mg/dL; nr. 2.5~7.0 mg/dL), and depressed levels of immunoglobulin (Ig) G (341 mg/dL; nr. 870~1700 mg/dL), IgA (15 mg/dL; nr. 110~410 mg/dL), IgM (10 mg/dL; nr. 46~260 mg/dL), IgD (<1.0 mg/dL; nr. ≤ 12.6 mg/dL), total protein (6.4 g/dL; nr. 6.7~8.3 g/dL), albumin (3.8 g/dL; nr. 3.9~4.9 g/dL), zinc turbidity test (ZTT; 1 KU; nr. 4~12 KU), serum Fe (50 μg/dL; nr. 54~181 μg/dL) and total cholesterol (106 mg/dL; nr. 130~219 mg/dL) were observed. Values of carcinoembryonic antigen (CEA), aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), creatine phosphokinase (CPK), amylase, blood urea nitrogen (BUN), creatinine, and electrolytes were within normal range. Titers of rheumatoid arthritis particle agglutination, anti-nuclear antibody, anti-microsome antibody, and anti-thyroglobulin antibody were within normal range. Her urine showed proteinuria (7.4 g/day). Lambda-type BJ protein was detected in her urine by immunofixation electrophoresis. Bone scintiscan using 99mTc-hydroxymethylene diphosphonate (HMDP) revealed multiple uptakes of radioisotope in generalized bones, particularly in vertebrae and shoulder joints. Chest and abdominal computed tomography scans revealed massive soft tissue masses around bilateral shoulder joints suggestive of amyloid light-chain (AL) deposition (shoulder-pad sign), paralytic ileus, small multiple mesenteric lymph nodes, small amount of ascites, slight right hydronephrosis, and slight splenomegaly. Skull X-ray films showed sporadic punched out lesions.

An iliac bone marrow (BM) puncture performed on 16 June 2015 showed that her BM was infiltrated by atypical medium-sized and large-sized myeloma cells with basophilic cytoplasm and fine chromatin networks with occasional nucleoli. Binuclear and trinuclear myeloma cells were frequently seen (Fig. 1). Myeloma cells accounted for 70.8% of total nucleated cells on smear preparation. On immunohistochemical examination, they were exclusively positive for light chain λ.
Fig. 1
Fig. 1

Bone marrow obtained before the initiation of treatment. a Bone marrow smear. Bone marrow is infiltrated by immature myeloma cells showing basophilic cytoplasm and fine nuclear chromatin networks with occasional nucleoli. Binuclear (yellow arrows) and trinuclear (black arrow) myeloma cells, suggesting hyperdiploidies, are seen (under × 40 magnification objective). b Electron micrograph of the bone marrow. Bone marrow is compactly occupied by immature myeloma cells with remarkable nucleoli, fine chromatin networks, and abundant rough endoplasmic reticula

A chromosomal analysis of the BM cells revealed complex hyperdiploidies (Fig. 2). Thus, a diagnosis of BJ-λ type MM (Durie and Salmon, stage IIIA; International Staging System, stage III; Southwest Oncology Group, stage III) was made.
Fig. 2
Fig. 2

Chromosome analysis showing complex hyperdiploidies. Hyperdiploidies were seen in three out of ten cells (3/10). Seven out of ten cells showed a normal karyotype (7/10). Similar hyperdiploidies remained until achieving stringent complete response

In the hematologic division of our hospital, most of the patients with MM are vulnerable older people with severe complications. Thus, the dose of Len is minimized to 10 mg/day in those patients to avoid the adverse effects, such as leukopenia, thrombocytopenia, toxicoderma, deep venous thrombosis, neuropathy, a high fever associated with elevated CRP (that is, transient inflammatory reaction), and so on. In fact, 10 mg of Len was found to be effective enough for treating MM with reduced adverse effects, and allowing for safe repetitions of treatments [6]. Moreover, doses of Bor and Dex are also reduced to improve tolerability and to optimize efficacy as suggested by Palumbo et al. [7].

The whole clinical course (Fig. 3), the detailed clinical course (Fig. 4), and regimens used during the whole clinical course are listed in Table 1. At first, three cycles of vincristine, adriamycin, and Dex (VAD) therapy were carried out. This treatment was fairly effective; levels of FLC-λ and BMG were depressed to 1140 μg/L from more than 3200 μg/L and to 2.2 mg/L from 6.5 mg/L, respectively. Bilateral shoulder joint pains and paralytic ileus were rapidly improved. She was released from confinement to bed and able to walk 3 weeks after starting the first cycle of VAD therapy. Although this regimen proved to be effective for relieving her symptoms, levels of FLC-λ still remained high (1140 mg/L). As shown in Table 1 and Fig. 3, regimens ~⑫ were consecutively carried out. In general, the regimens including Dex caused severe hyperglycemia which required insulin therapy, and most of them, except regimen in which CAM (400 mg/day for 3 weeks) was combined with Len and Dex, could not be efficiently repeated due to DM aggravation or inefficacy of the regimens. Of all the regimens, regimen (short dosing-period [sdp] Bor-Dex-CAM800), and the regimen ⑪/⑫ (sdpB(Reduced dose [Rd] RMinimized dose [Md]-CAM800) proved to be very effective. Levels of FLC-λ were drastically depressed to a normal range by regimens and ⑪ (Fig. 4). However, the former could not be repeated because of the aggravation of DM, leading to deterioration of the general condition of our patient. On the other hand, regimen ⑪ could be safely repeated without fearing DM aggravation; the levels of FLC-λ were brought down to a normal range (12.9 mg/L) with normal κ/λ ratio (1.024) after four cycles of this regimen (Table 1). Myeloma cells disappeared from her BM (Figs. 3 and 4) and BJ proteins disappeared from her serum and urine. Two color flow cytometric analysis of the BM showed absence of clonal plasma cells (PCs). In addition, levels of serum IgG, IgA, and IgM elevated to normal levels. Thus, our patient was proved to be in sCR according to the updated criteria of International Myeloma Working Group (IMWG) [8]. In May 2017, urticaria started to appear after subcutaneous (sc) injections of Bor. Thus, the administration of Bor was reduced to once a week from twice a week (regimen ⑫: sdpBRedRMd-CAM800) and intravenous administration of hydrocortisone 100 mg, prior to each Bor injection, was started to prevent urticaria. Regimen ⑫ was safely repeated without fearing DM aggravation as well as urticaria. Levels of FLC-λ remained within normal range, and our patient is in good condition as of November 2017.
Fig. 3
Fig. 3

Whole clinical course of the patient. Regimen (VAD) was fairly effective for reducing free light chain. Levels of free light chain-λ were depressed to 1140 mg/L from more than 3200 mg/L. Afterwards, various combination chemotherapies were carried out; however, the responses to some regimens were insufficient or other regimens, including Dex, although effective, were inappropriate to continue the treatments due to aggravation of diabetes mellitus. Stringent complete response was achieved by initiation of regimen ⑪ (sdpBRMd-CAM800). Levels of hemoglobin gradually elevated to a normal range, and platelet levels fluctuated within normal range. Faint blue areas indicate hospitalization. VAD; RMdD; RMdD-CAM400; sdp BD; BRedD; PD; sdp BD; VAD; sdp BD-CAM800; ⑩ sdp B-CAM800; ⑪ sdp BRMd-CAM800; ⑫ sdpBRedRMd-CAM800. BD Bor-Dex, BM bone marrow, BR Bor-Revlimid (lenalidomide), CAM clarithromycin, FLC free light chain, Md minimized dose, NCC nucleated cell count, PC plasma cell, PD pomalidomide-Dex, red reduced dose, sdp short dosing-period, VAD vincristine, adriamycin, and Dex

Fig. 4
Fig. 4

Detailed clinical course after September 2016. After the initiation of regimen ⑪ (sdpBRMd-CAM800),  stringent complete response was obtained and is still maintained with regimen ⑫ (sdpBRedRMd-CAM800) as of October 2017. Myeloma cells disappeared from BM and hyperdiploidies also disappeared. Regimen (sdpBD-CAM800) was also effective and the level of FLC-λ was depressed to normal range, but this treatment could not be continued due to aggravation of diabetes mellitus. BD Bor-Dex, BM bone marrow, BR Bor-Revlimid (lenalidomide), CAM clarithromycin, FLC free light chain, Md minimized dose, NCC nucleated cell count, PC plasma cell, PD pomalidomide-Dex, Red reduced dose, sdp short dosing-period, VAD vincristine, adriamycin, and Dex

Table 1

Brief summary of regimens used during the whole clinical course

Regimen

Cycles

Date of treatments

FLC-λ(mg/L)/BMG(mg/L)

Evaluation

VAD

3

Jun. 19~Sep.5/2015

≥ 3200→1140/6.5→2.2

Effective

RMdD

1

Sep.14 ~Oct. 4/2015

1140→1430/2.2→2.5

Ineffective

RMdD-CAM400

7

Oct. 12~May 15/2016

1430→439/2.5→1.5

Effective

sdp BD

2

May 16~Jun. 29/2016

439→72.9/1.5→1.3

Effective

BRedD

2

Jul. 11~Sep. 6/2016

72.9→496/1.3→1.5

Ineffective

PD

1

Sep. 13~Oct. 3/2016

496→805/1.5→1.9

Ineffective

sdpBD

1

Oct. 17~Oct. 30/2016

805→267/1.9→1.6

Fairly effective

VAD

1

Nov. 14~Dec. 6/2016

267→323/1.6→1.4

Ineffective

sdpBD-CAM800

2

Dec. 12~Jan. 23/2017

323→24.9/1.4→1.1

Very effective

⑩sdpB-CAM800

1

Feb. 4~Feb. 26/2017

24.9→148/1.1→2.1

Ineffective

⑪ sdpBRMd-cam800

4

Feb. 27~May 8/2017

148→12.9/2.8→2.1

Very effective

⑫ sdpBRedRMd-CAM800

6

May 23~Oct. 31/2017

12.9→14.2/2.1→1.4

Effective/stable

A (ADM) adriamycin, B bortezomib, BMG ß2-microglobulin, CAM clarithromycin, D (Dex) dexamethasone, FLC free light chain, Md minimized-dose, P (Pom) pomalidomide, R Revlimid (Len: lenalidomide), Red reduced dose, sc subcutaneous, sdp short dosing-period, V vincristine, wk week

VAD: V 0.4 mg/body·ADM 9 mg/m2, continuous intravenous infusion, on days 1–4; Dex 40 mg/body, on days1–4, 9–12, 17–20, every 4-wk cycle

RMdD: Len 10 mg/day for 3 wks; Dex 20 mg/day, twice/week for 3 wks, every 4-wk cycle

RMdD-CAM400: RMdD combined with CAM 400 mg/day, 200 mg twice/day for 3 wks, every 4-wk cycle

sdpBD: Bor 1.3 mg/m2, sc, twice/wk for 2 wks; Dex 20 mg/day twice/wk for 2 wks, every 4-wk cycle

BRedD: Bor 1.3 mg/m2, sc, once/wk for 4 wks; Dex 20 mg/day, twice/wk for 4 wks, every 6-wk cycle

PD: Pom 4 mg/day for 3 wks; Dex 20 mg/day twice/wk for 3 wks, every 4-wks cycle

sdpBD VAD

sdpBD-CAM800: sdpBD combined with CAM 800 mg/day, 400 mg twice/day for 2 wks, every 4-wk cycle

⑩sdpB-CAM800: Bor 1.3 mg/m2, sc, twice/wk for 2 wk; CAM 800 mg/day, 400 mg twice/day for 2 wks, every 4-wk cycle

⑪sdpBRMd-CAM800: Bor 1.3 mg/m2, sc, twice/wk for 2 wks; Len 10 mg/day for 2 wks; CAM 800 mg/day, 400 mg twice/day for 2 wks, every 4-wk cycle

⑫sdpBRedRMd-CAM800: Bor 1.3 mg/m2, sc, once/wk for 2 wks; Len 10 mg/day for 2 wks; CAM 800 mg/day, 400 mg twice/day for 2 wks, every 4-wk cycle

Discussion

It is important to elucidate the mechanisms whereby sCR is achieved by the combination regimen consisting of Len, Bor and CAM. Bor, the 26S proteasome inhibitor, has been widely used for treating MM [9]. Increasing lines of evidence indicate that inhibition of the 26S proteasome by Bor, that is, blocking of the ubiquitin proteasome system by Bor, leads to the accumulation of unfolded or misfolded protein in the endoplasmic reticulum (ER) in myeloma cells; this results in ER stress followed by a coordinated cellular response known as unfolded protein response (UPR) [1013]. UPR is known to induce activation of the chaperone protein GRP78 (Bip) to maintain ER integrity and upregulates transcription factor CHOP (the C/EBP homologous protein, also designated as GADD153) to mediate cell death when ER stress is beyond the tolerance of the cell adaptation [1013]. In the clinical field, Bor is now widely used in combination regimens such as VMP (Bor, melphalan, and prednisolone), VTD (Bor, thalidomide, and Dex), PVD (Pomalidomide, Bor, and Dex), or BRD (Bor, Len, and Dex) in refractory/relapsed MM or newly diagnosed MM. Although regimens involving Bor and Dex have contributed to substantial improvement of MM, the treatment of patients with MM associated with DM is still a troublesome issue, and therapeutic improvements are required.

As for CAM, many investigators have reported its immunosuppressive or immunomodulatory effects in patients with cancers or tumor-bearing animals. In brief, CAM is known to decrease the production of IL-1, IL-2, IL-5, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-α, TGF-β, and matrix metalloproteinase 9, and increase the production of IL-4, IL-12, and interferon–γ [6, 14, 15]. In addition, CAM is known to induce apoptosis through Fas-Fas ligand pathway [16].

Recently, the high efficacy of the chemotherapeutic regimen combining CAM (Biaxin®) with Len and Dex (BiRD regimen) in treating MM has been documented [17, 18]. Concerning the role of CAM in BiRD therapy, the steroid-enhancing/sparing effect is suggested [6, 14, 17, 19]; however, the exact mechanisms of action of CAM remain uncertain. Nakamura et al. [20] reported that CAM attenuates autophagy and induces cell growth inhibition in MM cells; more exactly, the treatment with CAM attenuates autophagy by blocking the late phase of the autophagic process, probably after the fusion of autophagosomes with lysosomes in myeloma cells.

Although CAM by itself exhibits no cytotoxicity [6, 12, 21], simultaneous inhibition of the ubiquitin-proteasome system by Bor and autophagy-lysosome system by CAM will synergistically lead to activate UPR, resulting in enhanced MM cell apoptosis [12, 22].

Since MM is characterized by uncontrolled cell growth of monoclonal antibody-producing neoplastic PCs, large quantities of unfolded or misfolded Ig production itself triggers ER stress [22]. This may mean that MM is a specific neoplasm susceptible to proteasome and autophagy inhibitors. In support of this proposal, Obeng et al. [11] reported that MM cells have a lower threshold for proteasome inhibitor-induced UPR induction and ER stress-induced apoptosis.

In BiRD regimen, CAM at a dose of 1000 mg/day, 500 mg twice a day, was recommended [17, 18]. In the present case, we applied a relatively high dose of CAM (800 mg/day, 400 mg twice a day, for 2 weeks) in regimens ~⑫, and succeeded in achieving and maintaining sCR by the regimen ⑪/⑫ without any severe adverse effects.

Len has generally been used in combination with Dex for treating refractory and relapsed MM [1], newly diagnosed MM [2, 3], and transplant-ineligible MM [4]. The precise cellular targets and the exact mechanisms of action of Len remain unclear. However, recent studies revealed that Len’s multiple effects include: (1) immune modulation (CD4+ and CD8+ T cell co-stimulation, regulatory T cell suppression, Th1 cytokine production, NK and NKT cell activation, and antibody-dependent cellular cytotoxicity), (2) interference with tumor micro-environment interactions (anti-angiogenesis, anti-inflammatory properties, downregulation of adhesion molecules, and anti-osteoclastogenic properties) and (3) direct anti-tumor effects (inhibition of cyclin-dependent kinase, induced expression of tumor suppressor genes such as Egr-1, Egr-2, and SPARC genes, downregulation of NF-κB, and inhibition of caspase 3, 8, and 9) [23]. Len is known to suppress TNF-α, IL-1β, IL-6, IL-12, TGF-β, macrophage inhibitory protein-α, granulocyte-macrophage colony-stimulating factor, insulin-like growth factor-1, basic FGF, RANKL, and vascular endothelial growth factor (VEGF), and to increase IL-2, IL-10, and interferon-γ. Inhibition of VEGF by Len may alter the BM microvasculature, thereby making the microenvironment less hospitable for MM cell growth [6, 2225]. Recently, Krönke et al. [26] demonstrated that Len causes selective ubiquitination and degradation of two lymphoid transcription factors – Ikaros family zinc finger proteins (IKZF) 1 and 3 (IKZF1, Ikaros; and IKZF3, Aiolos) – by the CRBN-CRL4 ubiquitin ligase. It is known that IKZF1 and IKZF3 are essential B cell transcription factors. A study in mice demonstrated that IKZF3 is required for the generation of PCs [27]. In this connection, Lu et al. [28] reported that Len-bound cereblon acquires the ability to target IKZF1 and IKZF3 for proteasomal degradation in MM cells. They analyzed myeloma cell lines and demonstrated that loss of IKZF1 and IKZF3 is necessary and sufficient for Len’s therapeutic effect. In the present case, we demonstrated that regimen ⑪/⑫ (sdpBRMd-CAM800 or sdpBRedRMd-CAM800) is highly effective for treating MM. Possibly, Len’s diverse apoptosis-inducing effects might further enhance cytotoxic effects of Bor and CAM.

In general, Dex is considered to be a requisite for treating MM, and it is included in most of the regimens for MM. However, in the present case, sCR was easily achieved by a Dex-free regimen (sdpBRMd-CAM800 or sdpBRedRMd-CAM800). This seems to indicate that Dex is not necessarily requisite in treating MM. Nevertheless, the effect of regimen (sdpBD-CAM800), which includes Dex, was equal to regimen ⑪ (sdpBRMd-CAM800), but the former was discontinued because of severe hyperglycemia which required insulin therapy. In contrast, the effect of Len-omitted regimen ⑩ (sdp B-CAM800) was ineffective. This means that the combination of three components, namely, Bor, Len, and CAM are requisite for treating MM.

It is well known that CAM is the potent CYP3A4 inhibitor and Bor is metabolized by CYP3A4. Therefore, concomitant administration of Bor and CAM may lead to intracellular elevation of Bor concentrations [12]. One may ask whether the enhanced cytotoxicity achieved by regimens including Bor and CAM is simply due to the pharmaco-interaction between Bor and CAM via CYP3A4. We cannot completely exclude this possibility.

Conclusions

In the present study, we clearly demonstrated that sdpBRMd-CAM800 or sdpBRedRMd-CAM800 regimen is highly effective for treating refractory MM. This regimen has outstanding merits as follows. (1) The regimen is Dex-free, therefore there is no risk of developing steroid-induced DM/DM aggravation or DM-related complications. (2) The regimen is based on a dose-reduction schedule, the adverse effects of Bor and Len are attenuated, and its medical cost is less expensive. (3) The regimen is based on a short-term schedule; it is less risky in developing various adverse effects and gives patients enough time to recover, enabling clinicians to repeat it safely. (4) The regimen contains CAM which might play an important role in enhancing synergistically the effects of Bor and Len. The sdpB(Red)RMd-CAM800  regimen is a promising combination therapy for patients with MM particularly associated with DM.

Abbreviations

BD: 

Bortezomib-dexamethasone

BJ: 

Bence-Jones

BM: 

Bone marrow

BMG: 

β2 microglobulin

Bor: 

Bortezomib

CAM: 

Clarithromycin

Dex: 

Dexamethasone

DM: 

Diabetes mellitus

ER: 

Endoplasmic reticulum

FLC: 

Free light chain

Ig: 

Immunoglobulin

IKZF: 

Ikaros family zinc finger proteins

IL: 

Interleukin

Len: 

Lenalidomide

MM: 

Multiple myeloma

nr.: 

Normal range

PC: 

Plasma cell

sCR: 

Stringent complete response

sdp: 

Short dosing-period

TGF: 

Transforming growth factor

TNF: 

Tumor necrosis factor

UPR: 

Unfolded protein response

VAD: 

Vincristine, adriamycin, and dexamethasone

VEGF: 

vascular endothelial growth factor

Declarations

Acknowledgements

The authors would like to thank Prof. Hong-Kean Ooi (Department of Veterinary Medicine, Azabu University) in helpful reviewing and preparing the manuscript.

Funding

This study was not supported by any grant.

Availability of data and materials

Not applicable

Authors’ contributions

NT carried out the clinical treatment, follow-up, and collecting data, and was also a major contributor in writing the manuscript. GI assisted in treating the patient. KH performed the mastectomy and postoperative follow-up. AO and MK performed the immunohistochemistry and were major contributors for the pathological diagnosis. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The patient was fully informed of the risk of modified treatments and the theoretical basis of the treatments for MM was explained to her.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published map and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Division of Hematology, Department of Internal Medicine, Imai Hospital, Tanaka-cho 100, Ashikaga Tochigi, 326-0822, Japan
(2)
Department of Internal Medicine, Imai Hospital, Tanaka-cho 100, Ashikaga Tochigi, 326-0822, Japan
(3)
Department of Surgery, Imai Hospital, Tanaka-cho 100, Ashikaga Tochigi, 326-0822, Japan
(4)
Department of Molecular and Cellular Pathology, School of Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa Ishikawa, 920-8640, Japan
(5)
Department of Diagnostic Pathology, Dokkyo Medical University School of Medicine, Shimotsuga-gun, Mibu-machi Tochigi, 321-0293, Japan

References

  1. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau J-L, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123–32.View ArticlePubMedGoogle Scholar
  2. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106(13):4050–3.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37.View ArticlePubMedGoogle Scholar
  4. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906–17.View ArticlePubMedGoogle Scholar
  5. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28(30):4621–9.View ArticlePubMedGoogle Scholar
  6. Takemori N, Fukuda T, Kojima M. Follow-up study of a multiple myeloma patient successfully treated with clarithromycin (CAM), low-dose lenalidomide and low-dose dexamethasone: significance and possible mechanism of action of CAM as an add-on therapy. Case Rep Clin Med. 2014;3:674–84.View ArticleGoogle Scholar
  7. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118(17):4519–29.View ArticlePubMedGoogle Scholar
  8. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587–600.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011;11(3):239–53.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Moriya S, Komatsu S, Yamasaki K, Kawai Y, Kokuba H, Hirota A, et al. Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress-mediated cell death in multiple myeloma cells. Int J Oncol. 2015;46(2):474–86.View ArticlePubMedGoogle Scholar
  11. Obeng EA, Carison LM, Gutman DM, Harrington Jr WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907–16.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Komatsu S, Miyazawa K, Moriya S, Takase A, Naito M, Inazu M, et al. Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells. Int J Oncol. 2012;40(4):1029–39.View ArticlePubMedGoogle Scholar
  13. Verfaillie T, Salazar M, Velasco G, Agostinis P. Linking ER stress to autophagy: potential implications for cancer therapy. Int J Cell Biol. 2010;2010:930509.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Takemori N, Kaneko H, Fukuda T, Kojima M. Follow-up study of Epstein-Barr virus-associated Hodgkin’s lymphoma (HL) developed in a patient with rheumatoid arthritis (RA) and analysis of circulating cytokines and clinical parameters: clarithromycin coupled with prednisolone is effective for preventing relapse of HL and controlling RA. Arch Clin Microbiol. 2015;6(4):6.Google Scholar
  15. Van Nuffel AM, Sukhatme V, Pantziarka P, Meheus L, Sukhatme VP, Bouche G. Repurposing drugs in oncology (ReDO)-clarithromycin as an anti-cancer agent. Ecancer. 2015;9:513.Google Scholar
  16. Ishimatsu Y, Kadota J, Iwashita T, Nagata T, Ishii H, Shikuwa C, et al. Macrolide antibiotics induce apoptosis of human peripheral lymphocytes in vitro. Int J Antimicrobial Agents. 2004;24:247–53.View ArticleGoogle Scholar
  17. Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2008;111(3):1101–9.View ArticlePubMedGoogle Scholar
  18. Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, et al. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol. 2010;85:664–9.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Fost DA, Leung DYM, Martin RJ, Brown EE, Szefler SJ, Spahn JD. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. J Allergy Clin Immunol. 1999;103:1031–5.View ArticlePubMedGoogle Scholar
  20. Nakamura M, Kikukawa Y, Takeya M, Mitsuya H, Hata H. Clarithromycin attenuates autophagy in myeloma cells. Int J Oncol. 2010;37:815–20.PubMedGoogle Scholar
  21. Moreau P, Huynh A, Facon T, Bouilly I, Sotto JJ, Legros L, et al. Lack of efficacy of clarithromycin in advanced multiple myeloma. Leukemia. 1999;13(3):490–1.View ArticlePubMedGoogle Scholar
  22. Moriya S, Che XF, Komatsu S, Abe A, Kawaguchi T, Gotoh A, et al. Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. Int J Oncol. 2013;42(5):1541–50.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24:22–32.View ArticlePubMedGoogle Scholar
  24. Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma. 2008;49(7):1238–45.View ArticlePubMedGoogle Scholar
  25. Richardson P, Mitsiades C, Laubach J, Schlossman R, Ghobrial I, Hideshima T, et al. Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2009;4:215–45.View ArticleGoogle Scholar
  26. Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301–5.View ArticlePubMedGoogle Scholar
  27. Coŕtés M, Georgopoulos K. Aiolos is required for the generation of high affinity bone marrow plasma cells responsible for long-term immunity. J Exp Med. 2004;199(2):209–19.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343:305–9.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement